- Home
- CRMD vs IOVA Comparison
CRMD vs IOVA Comparison
Compare CRMD & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- IOVA
- Stock Information
- Founded
- CRMD 2006
- IOVA 2007
- Country
- CRMD United States
- IOVA United States
- Employees
- CRMD N/A
- IOVA N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRMD Health Care
- IOVA Health Care
- Exchange
- CRMD Nasdaq
- IOVA Nasdaq
- Market Cap
- CRMD 925.6M
- IOVA 975.1M
- IPO Year
- CRMD 2010
- IOVA N/A
- Fundamental
- Price
- CRMD $13.09
- IOVA $2.42
- Analyst Decision
- CRMD Strong Buy
- IOVA Buy
- Analyst Count
- CRMD 8
- IOVA 11
- Target Price
- CRMD $17.57
- IOVA $11.90
- AVG Volume (30 Days)
- CRMD 4.6M
- IOVA 11.2M
- Earning Date
- CRMD 10-29-2025
- IOVA 11-06-2025
- Dividend Yield
- CRMD N/A
- IOVA N/A
- EPS Growth
- CRMD N/A
- IOVA N/A
- EPS
- CRMD 0.79
- IOVA N/A
- Revenue
- CRMD $121,484,498.00
- IOVA $241,525,000.00
- Revenue This Year
- CRMD $404.81
- IOVA $67.40
- Revenue Next Year
- CRMD $56.11
- IOVA $56.32
- P/E Ratio
- CRMD $16.53
- IOVA N/A
- Revenue Growth
- CRMD 14970.29
- IOVA 636.99
- 52 Week Low
- CRMD $5.60
- IOVA $1.64
- 52 Week High
- CRMD $17.43
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- CRMD 51.16
- IOVA 50.57
- Support Level
- CRMD $12.73
- IOVA $2.27
- Resistance Level
- CRMD $13.83
- IOVA $2.50
- Average True Range (ATR)
- CRMD 0.78
- IOVA 0.15
- MACD
- CRMD -0.16
- IOVA 0.00
- Stochastic Oscillator
- CRMD 44.67
- IOVA 47.69
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.